CDNA
Price
$17.28
Change
-$0.09 (-0.52%)
Updated
Apr 4 closing price
Capitalization
548.33M
26 days until earnings call
VCYT
Price
$28.95
Change
+$0.48 (+1.69%)
Updated
Apr 4 closing price
Capitalization
1.66B
38 days until earnings call
Ad is loading...

CDNA vs VCYT

Header iconCDNA vs VCYT Comparison
Open Charts CDNA vs VCYTBanner chart's image
CareDx
Price$17.28
Change-$0.09 (-0.52%)
Volume$1.03M
Capitalization548.33M
Veracyte
Price$28.95
Change+$0.48 (+1.69%)
Volume$1.31M
Capitalization1.66B
CDNA vs VCYT Comparison Chart
Loading...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCYT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDNA vs. VCYT commentary
Apr 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDNA is a StrongBuy and VCYT is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 06, 2025
Stock price -- (CDNA: $17.28 vs. VCYT: $28.95)
Brand notoriety: CDNA and VCYT are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CDNA: 124% vs. VCYT: 135%
Market capitalization -- CDNA: $548.33M vs. VCYT: $1.66B
CDNA [@Medical Specialties] is valued at $548.33M. VCYT’s [@Medical Specialties] market capitalization is $1.66B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDNA’s FA Score shows that 0 FA rating(s) are green whileVCYT’s FA Score has 0 green FA rating(s).

  • CDNA’s FA Score: 0 green, 5 red.
  • VCYT’s FA Score: 0 green, 5 red.
According to our system of comparison, CDNA is a better buy in the long-term than VCYT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDNA’s TA Score shows that 3 TA indicator(s) are bullish while VCYT’s TA Score has 4 bullish TA indicator(s).

  • CDNA’s TA Score: 3 bullish, 6 bearish.
  • VCYT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, VCYT is a better buy in the short-term than CDNA.

Price Growth

CDNA (@Medical Specialties) experienced а -3.79% price change this week, while VCYT (@Medical Specialties) price change was -3.88% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -6.38%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was -1.88%.

Reported Earning Dates

CDNA is expected to report earnings on May 01, 2025.

VCYT is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Medical Specialties (-6.38% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VCYT($1.66B) has a higher market cap than CDNA($548M). CDNA YTD gains are higher at: -19.290 vs. VCYT (-26.894). VCYT has higher annual earnings (EBITDA): -49.41M vs. CDNA (-84.92M). CDNA has more cash in the bank: 235M vs. VCYT (216M). VCYT has less debt than CDNA: VCYT (12.6M) vs CDNA (34.2M). VCYT has higher revenues than CDNA: VCYT (361M) vs CDNA (280M).
CDNAVCYTCDNA / VCYT
Capitalization548M1.66B33%
EBITDA-84.92M-49.41M172%
Gain YTD-19.290-26.89472%
P/E RatioN/AN/A-
Revenue280M361M78%
Total Cash235M216M109%
Total Debt34.2M12.6M271%
FUNDAMENTALS RATINGS
CDNA vs VCYT: Fundamental Ratings
CDNA
VCYT
OUTLOOK RATING
1..100
707
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
82
Overvalued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
5287
PRICE GROWTH RATING
1..100
6160
P/E GROWTH RATING
1..100
6054
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VCYT's Valuation (82) in the Biotechnology industry is in the same range as CDNA (96) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to CDNA’s over the last 12 months.

VCYT's Profit vs Risk Rating (88) in the Biotechnology industry is in the same range as CDNA (100) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to CDNA’s over the last 12 months.

CDNA's SMR Rating (52) in the Medical Specialties industry is somewhat better than the same rating for VCYT (87) in the Biotechnology industry. This means that CDNA’s stock grew somewhat faster than VCYT’s over the last 12 months.

VCYT's Price Growth Rating (60) in the Biotechnology industry is in the same range as CDNA (61) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to CDNA’s over the last 12 months.

VCYT's P/E Growth Rating (54) in the Biotechnology industry is in the same range as CDNA (60) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to CDNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDNAVCYT
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 13 days ago
84%
Bullish Trend 12 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 5 days ago
81%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCYT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MEURX26.85N/A
N/A
Franklin Mutual International Value Z
ATGAX31.85N/A
N/A
Cantor Fitzgerald Equity Opp A
RGBBX36.48N/A
N/A
American Funds Global Balanced R2
TGWFX11.26N/A
N/A
Transamerica Large Growth R4
PBAKX14.31-0.34
-2.32%
BlackRock Tactical Opportunities K

CDNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with BLFS. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then BLFS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDNA
1D Price
Change %
CDNA100%
-0.52%
BLFS - CDNA
41%
Loosely correlated
-6.95%
MTD - CDNA
41%
Loosely correlated
-6.63%
VCYT - CDNA
41%
Loosely correlated
+1.69%
NTRA - CDNA
40%
Loosely correlated
-3.49%
A - CDNA
36%
Loosely correlated
-6.08%
More